Results 191 to 200 of about 1,859,901 (381)
ESC Heart Failure, Volume 12, Issue 2, Page 733-760, April 2025.Abstract Implantable cardioverter defibrillators (ICDs) reliably prevent death due to life‐threatening arrhythmias; this may become less relevant in people with more severe heart failure who are reaching the end of life (EOL). This review aimed to explore the ICD deactivation process and identify ethical issues, especially around the initiation of ...
Siobhan C. Murray +2 more
wiley +1 more source
Time to move away from an oxygen-centric model of pulmonary infarction? - Authors' reply. [PDF]
Lancet Respir Med, 2021 McGonagle D, Bridgewood C, Meaney JFM.
europepmc +1 more source
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues
ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang +7 more
wiley +1 more source
Fan-shaped ground-glass opacity (GGO) as a premonitory sign of pulmonary infarction: a case report.
Journal of Thoracic Disease, 2018 T. Shinohara +5 more
semanticscholar +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler +4 more
wiley +1 more source
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. [PDF]
, 2015 BackgroundThis first-in-human study evaluated AMG 208, a small-molecule MET inhibitor, in patients with advanced solid tumors.MethodsThree to nine patients were enrolled into one of seven AMG 208 dose cohorts (25, 50, 100, 150, 200, 300, and 400 mg ...
Amore, Benny +14 more
core +2 more sources
Current concepts in the management of cardiogenic shock
Research Reports in Clinical Cardiology, 2014 Richard G TrohmanCardiology, Electrophysiology, Arrhythmia and Pacemaker Service, Department of Medicine, Rush University Medical Center, Chicago, IL, USAAbstract: Cardiogenic shock most commonly results from myocardial infarction and is associated with ...
Trohman RG
doaj
Left Atrium Thrombi Extending From Pulmonary Vein Thrombi Are Heterogeneous, Exhibit Calcifications, and Can Cause Acute Myocardial Infarction [PDF]
Hidekazu Takeuchi
openalex +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen +4 more
wiley +1 more source